Clinical trials: Cardiogenic Shock, ECMO
Cardiogenic Shock
The Effects of oXiris in Cardiogenic Shock Requiring VA-ECMO
Cardiogenic shock (CS) defines a state of systemic hypo-perfusion leading to end-organ dysfunction related to cardiac pump failure and with mortality rates in the range of 27-50% according to recent reviews.
- Trial name
- CLEAN ECMO (NCT05642273)
- Testing
- oXiris membrane, Blood tests
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Cardiogenic Shock, Cardiac Arrest
Outcomes of Patients With Venoarterial Extracorporeal Membrane Oxygenation
Venoarterial extracorporeal membrane oxygenation (VA ECMO)-also referred to as extracorporeal life support-is a form of temporary mechanical circulatory support and simultaneous extracorporeal gas exchange.
- Trial name
- NCT04039594
- Testing
- VA ECMO
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Anzhen Hospital
Cardiogenic Shock, Cardiac Arrest
Outcome of Patients Treated With ECLS
Extracorporeal life support (ECLS), also called extracorporeal membrane oxygenation (ECMO), is an extracorporeal technique of providing effective circulatory and (or) respiratory failure, with a growing number of critically ill…
- Conditions
- Cardiogenic Shock, Cardiac Arrest, Heart Failure, Acute Respiratory Failure
- Trial name
- NCT04405817
- Testing
- ECMO
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Nanjing Medical University
Respiratory Distress Syndrome, Adult, Respiratory Insufficiency
Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005
Extracorporeal membrane oxygenation (ECMO) is a means of artificially performing the function of the human lung and/or heart outside the body.
- Conditions
- Respiratory Distress Syndrome, Adult, Respiratory Insufficiency, Shock, Cardiogenic
- Trial name
- NCT00157144
- Where
- Australia
- Sponsor
- Bayside Health
Cardiogenic Shock
CARDSUP - SWISS Circulatory Support Registry
The project's main goal is to collect baseline clinical and procedural data as well as to assess clinical outcomes for all patients undergoing ECMO or Impella implantation at all included sites.
- Trial name
- CARDSUP (NCT04117230)
- Where
- 5 sites in Switzerland
- Volunteers
- 1,500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cardiogenic Shock
A Study on the Effects of Left Ventricular Unloading in the Setting of VA ECMO Support
REMAP ECMO is a registry based platform in which multiple response adaptive randomized clinical trials (trial domains) will be embedded.
- Trial name
- REMAP ECMO (NCT05913622)
- Testing
- Intra-aortic balloon pump
- Where
- 14 sites in Belgium, Netherlands
- Volunteers
- 430 people
- Sponsor
- Erasmus Medical Center
Cardiogenic Shock
Pharmacokinetic Modelling of Levosimendan in Adults
In the light of current knowledge of the PK of levosimendan and its use in ECMO weaning, deciphering the mechanisms of inter-individual variability in exposure and response to levosimendan appears essential in order to better…
- Trial name
- MILADECMO (NCT06993584)
- Testing
- Adult patients in cardiogenic shock
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Rouen
Acute Respiratory Distress Syndrome, Cardiogenic Shock
Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)
Study of immunosuppression biomarkers in patients with ARDS or cardiogenic shock with ECMO / ECLS, compared to patients with ARDS or cardiogenic shock without ECMO / ECLS
- Trial name
- IMPEC (NCT03262155)
- Testing
- Blood test
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Rennes University Hospital
Acute Myocardial Infarction, Cardiogenic Shock
Extracorporeal Life Support in Cardiogenic Shock
The aim of the study is to examine whether treatment with extracorporeal life support (ECLS) in addition to revascularization with percutaneous coronary intervention (PCI) or alternatively coronary artery bypass grafting (CABG)…
- Trial name
- ECLS-SHOCK (NCT03637205)
- Testing
- ECLS insertion, Revascularisation and optimal medical treatment
- Where
- 46 sites in Germany, Slovenia
- Volunteers
- 420 people
- Sponsor
- Helios Health Institute GmbH
Cardiogenic Shock
Early Left Atrial Septostomy Versus Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation
The use of venoarterial-extracorporeal membrane oxygenation(VA-ECMO) was associated with lower in-hospital mortality in patients with cardiogenic shock. However, VA-ECMO has a deleterious effect for hemodynamics.
- Trial name
- EARLY-UNLOAD (NCT04775472)
- Testing
- Early left atrial septostomy within 12 hours after VA-ECMO implantation, Selective left atrial septostomy
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- Chonnam National University Hospital
Cardiac Rhythm Disorder
Incidence and Morbidity of Cardiac Rhythm Disorders in Patients Assisted by ECMO-VA for Refractory Cardiogenic Shock
Brief Summary : Rhythm disorders are a frequent and potentially serious complication of critical patients in the ICU and postoperative cardiac surgery.
- Trial name
- CAVA-ECMO (NCT05788120)
- Testing
- Follow up by phone call
- Where
- 20 sites in France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Severe Aortic Stenosis, Cardiogenic Shock
Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR
The goal of this clinical trial is to evaluate the feasibility, effectiveness, and safety of pre-emptive left atrial veno-arterial extracorporeal membrane oxygenation (LAVA-ECMO) in patients undergoing complex and high-risk…
- Conditions
- Severe Aortic Stenosis, Cardiogenic Shock, Cardiogenic Shock, ECMO, Trans-catheter Aortic Valve Implantation
- Trial name
- PROTECT-TAVR (NCT07309029)
- Testing
- Left Atrial Veno-Arterial Extracorporeal Membrane Oxygenation (LAVA-ECMO)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Atlantic Health System
Acute Kidney Injury, Cardiogenic Shock
Acute Kidney Injury in Adult Patients Supported by VA-ECMO
Post-cardiotomy cardiogenic shock (PCCS) occurs in 2-6% of patients undergoing cardiac surgery, and 1% of cardiac surgery patients will require mechanical circulatory support using Veno-Arterial ExtraCorporeal Membrane…
- Trial name
- AKI-ECMO (NCT04082312)
- Testing
- No intervention
- Where
- France
- Volunteers
- 347 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Cardiac Arrest, Cardiopulmonary Arrest
ECMELLA vs. ECMO on 30-day Mortality
This international, multicenter cohort study aims to investigate outcomes after treatment with extracorporeal cardiopulmonary resuscitation (eCPR) during cardiac arrest.
- Conditions
- Cardiac Arrest, Cardiopulmonary Arrest, Extracorporeal Membrane Oxygenation Complication, Cardiogenic Shock
- Trial name
- NCT05175898
- Testing
- VA-ECMO, ECMELLA
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Extracorporeal Life Support, Hypotension
Hypotension During Extracorporeal Circulatory Support Indicated for Cardiogenic Shock
The cardiogenic shock is characterized by an alteration of organs function following a decrease in cardiac output linked to an impairment of cardiac performance. The prognosis remains poor with mortality between 40 and 50%.
- Conditions
- Extracorporeal Life Support, Hypotension, Vasoplegia
- Trial name
- RetroECMO-VP (NCT03968926)
- Testing
- Arterial pressure management during circulatory support by VA-ECMO
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Montpellier
COVID, SARS-CoV-2
European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO
In the last 10 years, severe acute respiratory infection (SARI) was responsible of multiple outbreaks putting a strain on the public health worldwide.
- Conditions
- COVID, SARS-CoV-2, ARDS, Human, Refractory Hypoxemia
- Trial name
- EuroECMO-COVID (NCT04366921)
- Where
- 97 sites in Austria, Belgium and 17 more
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
Cardiogenic Shock, Acute Myocardial Infarction
Oxidant-antioxidant Activity, Free Radicle Activity, Immune Response and Biomarkers in Extracorporeal Membrane Oxygenation (ECMO) Patients
We would like to investigate novel diagnostic methods or biomarkers to early predict the success of ECMO therapy for cardiogenic shock patients during the early stage after ECMO treatment.
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction, Myocarditis, Cardiomyopathy
- Trial name
- ECMO (NCT01089036)
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Cardiogenic Shock, Extracorporeal Membrane Oxygenation
Feasibility and Safety of Total Percutaneous Closure of Femoral Arterial Access Sites in the Veno-arterial ECMO Patients
The most frequent access site for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is the common femoral artery (CFA), using either an open or percutaneous technique.
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation, Myocarditis, Hypertension, Pulmonary
- Trial name
- NCT04689451
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cardiogenic Shock
Impella CP With VA ECMO for Cardiogenic Shock
Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is indicated as a haemodynamic rescue strategy in decompensated acute or chronic heart failure presenting as cardiogenic shock.
- Trial name
- REVERSE (NCT03431467)
- Testing
- Impella-CP LV Vent
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Pennsylvania
Cardiogenic Shock, Renal Replacement Therapy
REnal reCOVery After ECMO for Cardiogenic Shock (RECOVECMO)
This retrospective study assesses long term renal outcome in patients having suffered medical or post cardiotomy refractory cardiogenic shock requiring renal replacement therapy (RRT) concomitant with veno-arterial extracorporeal…
- Conditions
- Cardiogenic Shock, Renal Replacement Therapy, Venoarterial Extracorporeal Membrane Oxygenation
- Trial name
- RECOVECMO (NCT05788211)
- Testing
- standard of care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- University Hospital, Bordeaux